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Plasmids expressing Gl and G2 cyclins were introduced into the Saos-2 cell system monitoring p53-mediated transactivation [(1993) Oncogene 8, 
5431. Cyclin E, but not other cyclins, enhanced the p53-mediated transactivation about 2-fold. Co-transfectton of a CDK2 expression plasmid caused 
a 30% increase in the extent of the pS3-mediated transactivation. Moreover, the transfected ~53 protein became phosphorylated coordmately with 
the enhanced transactivation. The close correlation between transactivatton and p53 phosphorylatton suggests that phosphorylation is mvolved 
in positive regulation for the transactivatton by ~53. 
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1. INTRODUCTION 
Wild-type (wt) ~53 has been implicated in the control 
of cell proliferation and tumor suppression [l]. Like 
another tumor suppressor, the retinoblastoma suscepti- 
ble gene, the wt but not the mutant type (mt) ~53 is 
known to down-regulate the activity of various promot- 
ers [2]. Recently, Seto et al. [3] reported that the wt ~53 
can bind directly to the TATA box-binding protein, 
resulting in repression of transcription from TATA- 
containing promoters. In contrast, the wt p53 enhances 
transcription from the promoters containing the 33- 
base pair p53-binding sequence [4] detected in the ribo- 
some non-transcribed spacer region 3.5 kb upstream of 
the 45 S rRNA start site [5]. The p53-mediated transac- 
tivation is abrogated by DNA tumor virus oncogene 
products which are able to bind to wt ~53, such as SV4O 
large T antigen [6-81, adenovirus ElB product [9], and 
human papilloma virus E6 product [7]. In the virus 
uninfected cells, the mdm2 gene product is supposed to 
be a candidate for the modulator of ~53 [lo], although, 
in addition to wt, mt ~53 can also bind to the mdm2 
product [ 111. 
In this report, we studied the effects of Gl and G2 
cyclins and cyclin-dependent kinases on the p53-medi- 
ated transactivation in order to exploit the modulator 
of wt ~53 in normal cells. The results showed that cyclin 
Correspondence uddresx K. Segawa. Department of Microbiology, 
Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, 
Tokyo 160. Japan. Fax: (81) (3) 3353 01451. 
E enhances p53-mediated transactivation and phospho- 
rylation of ~53 protein in the transfection cells. 
2. MATERIALS AND METHODS 
2.1. Plasmids 
cDNAs encoding cyclin A [12], cyclin C, Dl and E [13], and cyclin 
Bl and B2 (Ntshimoto. T., unpublished) were subcloned into pcDL- 
SR 296 [14] at the ClaIIEcoRI, EcoRILKpnI, or ClaI-KpnI site. The 
CDC2 and CDK2 expression plasmids, pMEl8S-CDC2 and 
pME18S-CDK2, respectively, were described previously [15]. 
pMSVcL and ptk53CAT used for chloramphenicol acetyltransferase 
(CAT) assays were previously described [8]. 
2.2. Transfection and CAT assa) 
Saos-2 cells (1 x lo6 cells) were transfected with 1 pg of ptk53CAT. 
10 pg of cyclin expression plasmids and 4 /g of pRSVp-gal for 18 h 
as described previously [8]. Cells were re-fed with new growth medmm 
and incubated for 36 h. Cellular extracts were prepared and subjected 
to CAT assays as described [8]. Transfection efficiencies were normal- 
ized by the P-galactostdase activities from co-transfected pRSVpga1 
[8]. All CAT assays were repeated more than five times and the repro- 
ducibility of results was confirmed. 
2.3. Histone Hl kinase assa) 
Saos-2 cells transfected with 10 pg of pMSVcL, 10 pg of cyclin E 
expression plasmid, with or wtthout 10 pg of CDK2 expression plas- 
mid, were lysed with RIPA buffer contaming 1% Trtton X-100, 0.1% 
SDS 50 mM Tris-HCl (pH 7.5). and 1% trasylol (Sigma). The cell 
extracts were incubated with anti-cyclin E antibody [16] (2~1). normal 
rabbit sera (2 ~1). or anti-p53 antibody (1 ~1, pAb421, Oncogene Sci. 
Inc.) at 4°C for 2 h. Immune complexes were collected by adding 
protein A-Sepharose beads and subjected to histone Hl kmase assay 
as described [16]. 
2.4. Phosphorylation ofp53 
Saos-2 cells were transfected with ~53, cychn E and/or CDK2 ex- 
pression plasmids. At 36 h after transfection, cells were labeled with 
[“Plorthophosphate (1 .O mCi/ml; ICN) for 4 h. Cellular extracts pre- 
pared as descrtbed above were subJected to immunoprecipitation with 
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anti-p53 antibody (pAb421). followed by SDS-PAGE. 
Phosphorylated p53 was detected by autoradiography. 
3. RESULTS 
3.1. Modulation of p53-mediated transactivation bl* cy- 
clin expression plasmids 
The wt ~53 plays a crucial role in Gl arrest [17], 
enabling us to study the effect of cell cycle-specific cy- 
clins on the modulation of p53-mediated transactiva- 
tion. The plasmids encoding cyclins A. Bl, B2, C. Dl, 
and E, were placed under the control of SRa: promoter 
[14]. These plasmids were transfected to p53-null Saos-2 
cells with the ~53 expression plasmid, pMSVcL. and the 
reporter plasmid, ptk53CAT or ptkCAT, as described 
previously [8]. The CAT activities detected in the pres- 
ence of cyclin expression plasmids were compared with 
those in the absence of the plasmids. The CAT activity 
of the cyclin E-transfected extract was reproducibly in- 
creased about 2-fold, when ptk53CAT. but not 
ptkCAT, was used as a reporter plasmid (Fig. 1). Co- 
transfection with the plasmid encoding CDK2, which is 
known to be associated with cyclin E in vivo [ 161. caused 
a 30% increase in the extent of the p53-mediated 
transactivation, as compared with that in the cells trans- 
fected with cyclin E only (Fig. 1). Transfection with only 
CDK2 expression plasmid did not enhance CAT activ- 
ity. In contrast, the introduction of cyclin C decreased 
CAT activity by about 50%. However, the CAT activity 
was recovered by co-transfection with CDC2 or CDK2 
expression plasmid. Upon transfection with other cy- 
clins, there were no changes in CAT activities. 
To study the expression of cyclin E in the transfected 
cells, cellular extracts were immunoprecipitated with 
anti-cyclin E antibody or control normal rabbit sera, 
followed by histone Hl kinase assay (Fig. 2). The his- 
tone Hl kinase activity associated with cyclin E, if any, 
was faintly detected in the cyclin E-untransfected cells. 
By co-transfection with the cyclin E expression plasmid, 
however, the extent of histone H 1 phosphorylation was 
clearly increased. Moreover, the introduction of CDK2 
expression plasmid further enhanced phosphorylation 
of histone Hl by 4 times. No phosphorylated bands 
were detected in the immunoprecipitated extracts with 
normal rabbit sera (Fig. 2B). These results indicate that 
cyclin E is definitely expressed in the transfected cells. 
3.2. Phosphorylation of p53 in the transfected cells 
We then examined the phosphorylation of ~53 under 
conditions that the enhanced p53-mediated transactiva- 
tion and histone Hl kinase activity were detected. The 
transfected cells were labeled with [3’P]phosphate and 
immunoprecipitated with anti-p53 antibody. The band 
of phosphorylated ~53 was faintly detected in the cells 
transfected with ~53 expression plasmid only (Fig. 3, 
lane 3). By co-transfection with cyclin E (lane 2). or 
cyclin E plus CDK2 expression plasmids (lane l), the 
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Fig. 1. Transactication by p53 in the presence of cyclin and/or cell 
cycle control kmase genes. Saos-2 cells were transfected with 
ptk53CAT or ptkCAT (1 fig), pMSVcL (5 p(g), cyclm expresslon 
plasmid (10 pg) shown as a capttal letter below the figure, and/or cell 
cycle control kinase expression plasmids (CDC2 and CDKZ). The 
CAT activities m the extracts from the transfected cells were measured 
as described [8]. The relative CAT activities compared with the control 
value obtained from the ceil extract transfected with ptk53CAT. 
pMSVcL. and backbone plasmid pcDL-SRa296 are shown as closed 
bars. Hatched and open bars represent the values obtamed from 
CDKZ or CDCZ ewpresslon plasmid-transfected cells, respectively 
extent of phosphorylation was dramatically increased. 
These results indicate that ~53 is more heavily 
phosphorylated in cells in which enhanced transactiva- 
tion was observed. 
4. DISCUSSION 
Various Gl and G2 cyclin expression plasmids were 
transfected in the p53-mediated transactivation moni- 
toring system reported previously [S]. Only cyclin E. but 
not the other Gl and G2 cyclins, reproducibly enhanced 
transcription from the promoter containing the p53- 
binding sequence (Fig. 1). Moreover. the co-transfec- 
tion of the plasmid encoding CDK2, which is known to 
be associated with cyclin E in vivo [16], further en- 
hanced CAT activity (Fig. 1). In parallel with the ele- 
vated transactivation, the extent of ~53 phosphoryla- 
tion in the transfected cells was also increased (Fig. 3). 
The close correlation between transactivation and ~53 
phosphorylation suggests that phosphorylation is in- 
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volved in the positive regulation of the transactivation 
by ~53. Recently, Hupp et al. [18] reported that phos- 
phorylation at the C-terminal site of p53 by casein ki- 
nase (CK) II is responsible for the activation of the 
DNA-binding ability of ~53. Thus, phosphorylation of 
p53 may allow very tight binding to the p53-binding 
sequence or may stabilize the complex of p53 and DNA, 
resulting in transcriptional activation, as in the case of 
the c-Fos/c-Jun heterodimer [ 191. Alternatively, phos- 
phorylation might affect the conformation of the N- 
terminus transactivation domain in ~53, as reported in 
the case of CREB [20]. It is important to study whether 
p53 is directly phosphorylated by cyclin E-CDK2 or by 
some other kinase(s) controlled via the cyclin E-CDK2 
system. To search for certain kinases for ~53, in vitro 
phosphorylation experiments using purified p53 and 
CDC2, CDK2 and CKII are in progress. 
A number of results support the hypothesis that Gl 
cyclins and cyclin-dependent kinases play crucial roles 
to control Gl progression [21]. Ohtsubo and Roberts 
[22] have recently published that the over-expression of 
cyclin E, but not other Gl cyclins, shortens the duration 
of Gl, decreases cell size, and diminishes the serum 
requirement for the transition from Gl to S. Therefore, 
the enhanced p53-mediated transactivation by cyclin E 
might be one of the important events controlling the 
transition from Gl to S. In this context. it should be 
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Fig. 2. Histone Hl kinase activity in cyclin E-transfected cells. Saos-2 
cells were transfected with 1 pg of ptk53CAT, 5 pg of pMSVcL m the 
presence of 20 pg of pcDLSRa296 (lane 1). 10 pg of pSRacyclin E 
and 10 pg of pcDL-SRa296 (lane 2), or 10 pg of pSRcccyclm E and 
10 pg of pMEl8S-CDK2 (lane 3). The cellular extracts were im- 
munoprecipttated with rabbit sera containing anti-cyclin E antibody 
[16] (A), or normal rabbit sera (B). followed by histone Hl kinase 
assay as described [16]. Only the regions exhibiting phosphorylated 
histone Hl bands discernible by autoradtography after analyzing by 
SDS-PAGE are shown. 
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Fig. 3. Phosphorylation of p53 in transfected cells. Saos-2 cells were 
transfected with 1 fig of ptk53CAT, 5 pg of pMSVcL in the presence 
of 10 pg of pSRacyclin E and 10 pg of pME18SCDK2 (lane l), 10 pg 
of pSRacyclin E and 10 pg of pcDL-SRa-296 (lane 2), or 20 pug of 
pcDL-SRa296 (lane 3). At 36 h post-transfection. cells were labeled 
wtth [“PIphosphate for 4 h and lysed with RIPA buffer. The extracts 
were subjected to immunoprectpitation with the ant]-p53 anttbody, 
pAb 421. The phosphorylated p53 bands were discerned by autoradi- 
ography after analyzing by SDS-PAGE. The molecular weight mark- 
ers used which are shown m numbers at the left side of the figure are 
(m kDa) phosphorylase b (97). bovine serum albumin (68). ovalbumm 
(45). and carbonic anhydrase (31). 
noted that the synthesis of p53 is increased in parallel 
with the transition from Gl to S [23], and the amount 
of cyclin E is maximal near the Gl-S boundary [16]. 
However, this assumption is irrelevant to the previously 
published findings that wt p53 stops cells at Gl [17] and 
transactivates gaad45 gene, which is responsible for 
growth arrest [24]. The discrepancy needs to be clarified 
by identifying cellular genes transactivated by wt p53 
and by analyzing their functions. 
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